Jianhong Zhong

Nanning, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Evaluation of the predictive accuracy of nine staging systems in patients with hepatocellular carcinoma: a multicenter, retrospective study in China.

Evaluation of the predictive accuracy of nine staging systems in patients with hepatocellular carcinoma: a multicenter, retrospective study in China.

Journal: Scientific reports

Published: March 01, 2026

The SAGES scoring model leads to personalized treatment via the combination of TACE, TKIs and ICIs for unresectable hepatocellular carcinoma.

The SAGES scoring model leads to personalized treatment via the combination of TACE, TKIs and ICIs for unresectable hepatocellular carcinoma.

Journal: Frontiers in immunology

Published: February 02, 2026

Correction to: Aptamer-Functionalized Fluorescent Silica Nanoparticles for Highly Sensitive Detection of Leukemia Cells.

Correction to: Aptamer-Functionalized Fluorescent Silica Nanoparticles for Highly Sensitive Detection of Leukemia Cells.

Journal: Discover nano

Published: October 01, 2025

Correction to: Aptamer combined with fluorescent silica nanoparticles for detection of hepatoma cells.

Correction to: Aptamer combined with fluorescent silica nanoparticles for detection of hepatoma cells.

Journal: Discover nano

Published: August 25, 2025

The SMIM25-COX-2 Axis Modulates the Immunosuppressive Tumor Microenvironment and Predicts Immunotherapy Response in Hepatocellular Carcinoma.

The SMIM25-COX-2 Axis Modulates the Immunosuppressive Tumor Microenvironment and Predicts Immunotherapy Response in Hepatocellular Carcinoma.

Journal: Current issues in molecular biology

Published: July 31, 2025

First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study.

First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study.

Journal: Signal transduction and targeted therapy

Published: February 10, 2025

Update on the clinical features, treatment and histogenesis of combined hepatocellular-cholangiocarcinoma.

Update on the clinical features, treatment and histogenesis of combined hepatocellular-cholangiocarcinoma.

Journal: Oncology letters

Published: December 07, 2024

Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study.

Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study.

Journal: Liver cancer

Published: October 12, 2024

Letter: Determining optimal ALT cut-off values for predicting significant hepatic histological changes in chronic hepatitis B virus infection.

Letter: Determining optimal ALT cut-off values for predicting significant hepatic histological changes in chronic hepatitis B virus infection.

Journal: Alimentary pharmacology & therapeutics

Published: April 09, 2024

Surgical treatment improves overall survival of hepatocellular carcinoma with extrahepatic metastases after conversion therapy: a multicenter retrospective study.

Surgical treatment improves overall survival of hepatocellular carcinoma with extrahepatic metastases after conversion therapy: a multicenter retrospective study.

Journal: Scientific reports

Published: December 17, 2023

Prognoses of Patients Treated With Surgical Therapy Versus Continuation of Local-Plus-Systemic Therapy Following Successful Down-Staging of Intermediate-Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study.

Prognoses of Patients Treated With Surgical Therapy Versus Continuation of Local-Plus-Systemic Therapy Following Successful Down-Staging of Intermediate-Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study.

Journal: The oncologist

Published: August 03, 2023

Systemic therapy with or without transcatheter intra-arterial therapies for unresectable hepatocellular carcinoma: a real-world, multi-center study.

Systemic therapy with or without transcatheter intra-arterial therapies for unresectable hepatocellular carcinoma: a real-world, multi-center study.

Journal: Frontiers in immunology

Published: January 05, 2023

Showing 1-12 of 29

Last Updated: 09/26/2026